Hahn SK - Search Results

1

Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis.

Kong WH, Park K, Lee MY, Lee H, Sung DK, Hahn SK. Kong WH, et al. Among authors: hahn sk. Biomaterials. 2013 Jan;34(2):542-51. doi: 10.1016/j.biomaterials.2012.09.067. Epub 2012 Oct 22. Biomaterials. 2013. PMID: 23092863

2

Effect of hyaluronic acid molecular weight on the morphology of quantum dot-hyaluronic acid conjugates.

Kim J, Park K, Hahn SK. Kim J, et al. Among authors: hahn sk. Int J Biol Macromol. 2008 Jan 1;42(1):41-5. doi: 10.1016/j.ijbiomac.2007.09.002. Epub 2007 Sep 11. Int J Biol Macromol. 2008. PMID: 17936350

3

Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.

Jiang G, Park K, Kim J, Kim KS, Hahn SK. Jiang G, et al. Among authors: hahn sk. Mol Pharm. 2009 May-Jun;6(3):727-37. doi: 10.1021/mp800176t. Mol Pharm. 2009. PMID: 19178144

4

Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization.

Oh EJ, Park K, Choi JS, Joo CK, Hahn SK. Oh EJ, et al. Among authors: hahn sk. Biomaterials. 2009 Oct;30(30):6026-34. doi: 10.1016/j.biomaterials.2009.07.024. Epub 2009 Jul 31. Biomaterials. 2009. PMID: 19647313

5

Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.

Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK. Oh EJ, et al. Among authors: hahn sk. J Control Release. 2010 Jan 4;141(1):2-12. doi: 10.1016/j.jconrel.2009.09.010. Epub 2009 Sep 13. J Control Release. 2010. PMID: 19758573 Review.

6

Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.

Kong JH, Oh EJ, Chae SY, Lee KC, Hahn SK. Kong JH, et al. Among authors: hahn sk. Biomaterials. 2010 May;31(14):4121-8. doi: 10.1016/j.biomaterials.2010.01.091. Epub 2010 Feb 10. Biomaterials. 2010. PMID: 20149450

7

Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.

Park K, Lee MY, Kim KS, Hahn SK. Park K, et al. Among authors: hahn sk. Biomaterials. 2010 Jul;31(19):5258-65. doi: 10.1016/j.biomaterials.2010.03.018. Epub 2010 Apr 7. Biomaterials. 2010. PMID: 20378167

8

Anti-Flt1 peptide - hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy.

Oh EJ, Choi JS, Kim H, Joo CK, Hahn SK. Oh EJ, et al. Among authors: hahn sk. Biomaterials. 2011 Apr;32(11):3115-23. doi: 10.1016/j.biomaterials.2011.01.003. Epub 2011 Jan 28. Biomaterials. 2011. PMID: 21277020

9

Target specific systemic delivery of TGF-β siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis.

Park K, Hong SW, Hur W, Lee MY, Yang JA, Kim SW, Yoon SK, Hahn SK. Park K, et al. Among authors: hahn sk. Biomaterials. 2011 Jul;32(21):4951-8. doi: 10.1016/j.biomaterials.2011.03.044. Epub 2011 Apr 11. Biomaterials. 2011. PMID: 21481451

10

Target-specific gene silencing of layer-by-layer assembled gold-cysteamine/siRNA/PEI/HA nanocomplex.

Lee MY, Park SJ, Park K, Kim KS, Lee H, Hahn SK. Lee MY, et al. Among authors: hahn sk. ACS Nano. 2011 Aug 23;5(8):6138-47. doi: 10.1021/nn2017793. Epub 2011 Jul 8. ACS Nano. 2011. PMID: 21739990

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

166 results

Search Page

Filters